3.22 – International Journal of Infectious Diseases

Treatment with Ivermectin Is Associated with Decreased Mortality in COVID-19 Patients: Analysis of a National Federated Database

Excerpts from this article:

From doctors at University of Miami

To evaluate the difference in mortality of patients treated with ivermectin vs patients treated with remdesivir with COVID-19 in United States using TriNetX Research network, a federated EMR network of over 44 healthcare organizations and 68 million patients from US, from 2009-2021.

We retrospectively identified adults (≥18 years) with a recorded COVID-19 infection between January 1, 2020 and July 11, 2021. We compared those with recorded use of ivermectin, but not remdesivir, against those with recorded use of remdesivir, but not ivermectin. 

There were a total of 1,761,060 possible COVID-19 patients based on ICD-10 diagnostic terms and confirmatory lab results. Prior to controlling, our analysis yielded 41,608 patients who had COVID-19 resulting in two unique cohorts that were treated with either ivermectin (1,072) or remdesivir (40,536).


Ivermectin use was associated with decreased mortality in patients with COVID-19 compared to remdesivir. ivermectin was associated with reduced mortality vs. remdesivir (OR 0.308, 95% CI (0.198,0.479)), Risk Difference -5.224%, CI (-7.079%,-3.369%), p <0.0001.

[Translated into layman’s language:  “Using ivermectin, mortality was reduced by 70% in the ivermectin group (vs. remdesivir) with a chance of 1 in 10,000,000 of its having happened by chance.”]

To our knowledge, this is the largest association study of patients with COVID-19, mortality and ivermectin.


1.15.22 – Cureus – Peer Reviewed Article

“Ivermectin Prophylaxis Used for COVID-19: A Citywide, Prospective, Observational Study of 223,128 Subjects Using Propensity Score Matching”


In a citywide ivermectin program with prophylactic, optional ivermectin use for COVID-19, ivermectin was associated with significantly reduced COVID-19 infection, hospitalization, and death rates from COVID-19.

Figure 2 – Summary of the Findings –

Ivermectin Use – 25 deaths from COVID-19 – 0.8%  mortality rate

Non-Ivermectin Use – 79 deaths from COVID-19 – 2.6% mortality rate

When comparing subjects that used ivermectin regularly, non-users were two times more likely to die from COVID-19 while ivermectin users were 7% less likely to be infected with SARS-CoV-2 (p = 0.003).